Astria Therapeutics, Inc.
ATXSDelisted Jan 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001454789
Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Astria Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 66 | 76 | +10 |
| Shares | 23.4M | 24.7M | +1.26M (+5.4%) |
| Value | $311.6M | $205.5M | −$106.1M (−34.1%) |
New holders (27)
Institutions that held Astria Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (17)
Institutions that held Astria Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Balyasny Asset Management LLC | 485,939 | $6.46M |
| Silverarc Capital Management, LLC | 93,823 | $1.25M |
| EAM Investors, LLC | 72,129 | $959.3K |
| Campbell & CO Investment Adviser LLC | 40,202 | $534.7K |
| Qube Research & Technologies Ltd | 34,068 | $453.1K |
| Marshall Wace, LLP | 30,994 | $412.2K |
| Mirabella Financial Services LLP | 28,585 | $380.2K |
| Cubist Systematic Strategies, LLC | 17,363 | $230.9K |
| Verition Fund Management LLC | 16,794 | $223.4K |
| Man Group plc | – | $168.7K |
| Diametric Capital, LP | 10,859 | $144.4K |
| LMR Partners LLP | 10,341 | $137.5K |
| Point72 Middle East FZE | 2,866 | $38.1K |
| Dorsey Wright & Associates | 2,042 | $27.2K |
| Benjamin F. Edwards & Company, Inc. | 333 | $4.00K |
| McIlrath & Eck, LLC | 83 | $1.10K |
| Advisory Services Network, LLC | 41 | $545 |